PMID: 
We are not aware of any publication which cites or mentions this structure.
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
Yu Y,
Jang M,
Miyashiro J,
Clark RF,
Zhu GD,
Gong J,
Dai Y,
Frey RR,
Penning TD,
Kim H,
Lee HK,
Kim JK,
Ryu KM,
Park SJ,
Yoon T,
Li T,
Kurnick MD,
Kapecki NJ,
Li L,
Gorman JV,
Montgomery DA,
Manaves V,
Bromberg KD,
Doktor SZ,
Thakur A,
Wang J,
Smith HA,
Buchanan FG,
Ferguson DC,
Torrent M,
Jakob CG,
Qiu W,
Upadhyay AK,
Martin RL,
Lai A,
Michaelides MR
J Med Chem (2024)
Abstract
TAM receptor tyrosine kinases have emerged as promising therapeutic targets for cancer treatment due to their roles in both tumor intrinsic survival mechanisms and suppression of antitumor immunity within the tumor microenvironment. Inhibiting MerTK and Axl selectively is believed to hinder cancer cell survival, reverse the protumor myeloid phenotype, and suppress efferocytosis, thereby eliciting an antitumor immune response. In this study, we present the discovery of
We are not aware of any publication which cites or mentions this structure.